why choose us

First received: November 07, 2022

Clinical Trial: A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hodgkin Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Brief Summary: To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.

Read more